Jump to content

AZD-7268

Add links
From Wikipedia, the free encyclopedia
AZD-7268
Clinical data
Other namesAZD7268; AZ12488024; AZ-12488024
Routes of
administration		Oral[1]
Drug classδ-Opioid receptor agonist[1]
Identifiers
  • N-(2-hydroxyethyl)-N-methyl-4-[quinolin-8-yl-[1-(1,3-thiazol-4-ylmethyl)piperidin-4-ylidene]methyl]benzamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
ECHA InfoCard100.205.777 Edit this at Wikidata
Chemical and physical data
FormulaC29H30N4O2S
Molar mass498.65 g·mol−1
3D model (JSmol)
  • CN(CCO)C(=O)C1=CC=C(C=C1)C(=C2CCN(CC2)CC3=CSC=N3)C4=CC=CC5=C4N=CC=C5
  • InChI=1S/C29H30N4O2S/c1-32(16-17-34)29(35)24-9-7-21(8-10-24)27(26-6-2-4-23-5-3-13-30-28(23)26)22-11-14-33(15-12-22)18-25-19-36-20-31-25/h2-10,13,19-20,34H,11-12,14-18H2,1H3
  • Key:ZJKUETLEJYCOBO-UHFFFAOYSA-N

AZD-7268 is a δ-opioid receptor agonist which was under development for the treatment of major depressive disorder but was never marketed.[1][2][3] It is taken by mouth.[1]

The affinity (Ki) of AZD-7268 for the δ-opioid receptor was reported to be 2.7 nM and its selectivity for this receptor over the μ-opioid receptor was reported to be 2,000-fold.[4] No animal studies of AZD-7268 appear to have been published.[3][4] In addition to putative antidepressant effects, AZD-7268 might have anxiolytic effects.[4][3] Structurally, AZD-7268 was derived from SNC-80.[4]

Dose-limiting side effects of AZD-7268 in clinical trials included syncope (fainting), hypotension (low blood pressure), and dizziness.[3]

AZD-7268 was first described by 2007.[3] Its development was discontinued in 2010.[3][1] It reached phase 2 clinical trials prior to the discontinuation of its development.[1] No reason was given for the discontinuation of its development.[3] However, the drug was found to be ineffective for major depressive disorder in a phase 2 clinical trial of 231 participants comparing it with placebo and escitalopram.[3][5][4][6] The drug was under development by AstraZeneca.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g "AZD 7268". AdisInsight. 5 November 2023. Retrieved 22 October 2024.
  2. ^ "Delving into the Latest Updates on AZD-7268 with Synapse". Synapse. 19 September 2024. Retrieved 22 October 2024.
  3. ^ a b c d e f g h Mandrioli R, Mercolini L (April 2015). "Discontinued anxiolytic drugs (2009 - 2014)". Expert Opin Investig Drugs. 24 (4): 557–573. doi:10.1517/13543784.2014.998335. PMID 25557457.
  4. ^ a b c d e Fujii H, Takahashi T, Nagase H (September 2013). "Non-peptidic δ opioid receptor agonists and antagonists (2000 - 2012)". Expert Opin Ther Pat. 23 (9): 1181–1208. doi:10.1517/13543776.2013.804066. PMID 23705966.
  5. ^ Sakurai H, Yonezawa K, Tani H, Mimura M, Bauer M, Uchida H (July 2022). "Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry". Pharmacopsychiatry. 55 (4): 193–202. doi:10.1055/a-1714-9097. PMC 9259184. PMID 35045580.
  6. ^ Connolly KR, Thase ME (March 2012). "Emerging drugs for major depressive disorder". Expert Opin Emerg Drugs. 17 (1): 105–126. doi:10.1517/14728214.2012.660146. PMID 22339643.


Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://wiki.riteme.site/w/index.php?title=AZD-7268&oldid=1259171915"